--- title: "Pliant Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295576257.md" datetime: "2026-08-11T20:28:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295576257.md) - [en](https://longbridge.com/en/news/295576257.md) - [zh-HK](https://longbridge.com/zh-HK/news/295576257.md) generator: "portal-rs" --- # Pliant Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.36, missing the estimate of USD -0.3372. EBIT: As of FY2026 Q2, the actual value is USD -22.37 M. ### Second Quarter 2026 Financial Results #### Operating Expenses - Research and development expenses decreased to - $16.7 million for the three months ended June 30, 2026, compared to - $32.2 million for the prior-year quarter. - General and administrative expenses decreased to - $7.1 million for the three months ended June 30, 2026, compared to - $13.4 million for the prior-year quarter. - Total operating expenses for the three months ended June 30, 2026, were - $23.862 million, down from - $45.592 million in the prior-year quarter. #### Net Loss - Net loss was - $22.4 million for the three months ended June 30, 2026, a decrease from - $43.3 million in the prior-year quarter. - Net loss per share - basic and diluted was - $0.36 for the three months ended June 30, 2026, compared to - $0.71 for the prior-year quarter. ### Six Months Ended June 30, 2026 Financial Results #### Operating Expenses - Research and development expenses were - $30.311 million for the six months ended June 30, 2026, compared to - $75.634 million for the same period in 2025. - General and administrative expenses were - $15.323 million for the six months ended June 30, 2026, compared to - $28.893 million for the same period in 2025. - Total operating expenses were - $45.634 million for the six months ended June 30, 2026, compared to - $104.527 million for the same period in 2025. - Loss from operations was - $45.634 million for the six months ended June 30, 2026, compared to - $104.527 million for the same period in 2025. #### Other Income and Expenses - Interest and other income (expense), net was $3.223 million for the six months ended June 30, 2026, compared to $6.669 million for the same period in 2025. - Interest expense was $0 for the six months ended June 30, 2026, compared to - $1.608 million for the same period in 2025. #### Net Loss - Net loss was - $42.411 million for the six months ended June 30, 2026, compared to - $99.466 million for the same period in 2025. - Net loss per share - basic and diluted was - $0.69 for the six months ended June 30, 2026, compared to - $1.62 for the same period in 2025. ### Balance Sheet Highlights (as of June 30, 2026) #### Cash and Investments - Cash, cash equivalents and short-term investments totaled $159.6 million as of June 30, 2026. - Cash and cash equivalents were $24.883 million as of June 30, 2026, down from $45.445 million as of December 31, 2025. - Short-term investments were $133.218 million as of June 30, 2026, down from $145.499 million as of December 31, 2025. #### Assets - Total current assets were $163.142 million as of June 30, 2026, compared to $196.448 million as of December 31, 2025. - Total assets were $189.881 million as of June 30, 2026, compared to $225.228 million as of December 31, 2025. #### Liabilities - Accounts payable increased to $1.531 million as of June 30, 2026, from $0.480 million as of December 31, 2025. - Accrued research and development increased to $9.028 million as of June 30, 2026, from $4.804 million as of December 31, 2025. - Accrued liabilities decreased to $3.653 million as of June 30, 2026, from $9.634 million as of December 31, 2025. - Total current liabilities were $16.484 million as of June 30, 2026, compared to $16.365 million as of December 31, 2025. - Total liabilities were $42.955 million as of June 30, 2026, compared to $44.023 million as of December 31, 2025. #### Stockholders’ Equity - Total stockholders’ equity was $146.926 million as of June 30, 2026, compared to $181.205 million as of December 31, 2025. - Accumulated deficit was - $901.807 million as of June 30, 2026, compared to - $859.396 million as of December 31, 2025. ### Operational Metrics and Outlook #### Oncology Program - Enrollment in the FORTIFY Phase 1b indication expansion trial for PLN-101095 is strong and progressing ahead of schedule, with interim data expected in 2027. - Updated PLN-101095 Phase 1 monotherapy biomarker data highlighted a coordinated T-cell reactivation cascade in responders. #### Integrin-Targeted Delivery Platform - Pliant Therapeutics, Inc. is advancing a platform to deliver drug payloads, such as siRNAs, to selective tissue types, with preclinical proof-of-concept studies currently ongoing. - The company plans to provide additional details on this platform, including initial treatment indications, in the second half of 2026. #### Corporate Highlights - Pliant Therapeutics, Inc. appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors, bringing extensive oncology drug development and commercialization expertise. #### Outlook - Pliant Therapeutics, Inc. expects its cash, cash equivalents, and short-term investments of $159.6 million as of June 30, 2026, to be sufficient to fund operations into the second half of 2028. - The company anticipates sharing more information on its proprietary integrin-targeted drug-delivery platform and its path forward, including initial treatment indications, in the second half of 2026. ### Related Stocks - [PLRX.US](https://longbridge.com/en/quote/PLRX.US.md) ## Related News & Research - [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md) - [PicS Q2 2026 Earnings Preview](https://longbridge.com/en/news/296709997.md) - [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md) - [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**